Robert Leadbetter

Robert (Bob) Leadbetter, M.D., is a board certified psychiatrist with over 20 years of experience in the pharmaceutical industry. After an initial career at the University of Virginia running a research unit specializing in treatment-refractory schizophrenia, he joined GSK with executive director responsibilities for programs in all stages of CNS clinical development. He was the clinical lead in obtaining FDA/MAA/other country approval of an anticonvulsant for bipolar disorder. In addition, he has had over 10 years of experience in pharmacovigilance and drug safety, including an FDA advisory committee presentation of the risk/benefit profile of a novel asthma biopharmaceutical resulting in NDA approval. More recently, he has been consulting with a variety of pharmaceutical and contract research companies regarding CNS clinical development and non-CNS safety issues.